Agilent

Qiagen's CEO discussed the company's focus on specific growth drivers, while Invitae's CEO talked about pandemic-related challenges in its genetic testing business.

Agilent said its qualitative assay is used for the postnatal diagnosis of copy-number alterations and copy-neutral loss of heterozygosity from DNA.

For the three months ended Oct. 31, revenues rose to $1.48 billion from $1.37 billion in Q4 2019, beating the average Wall Street estimate of $1.4 billion.

The agency approved Agilent/Dako's PD-L1 IHC test for identifying TNBC patients who are most likely to respond to Keytruda and chemo.

The team plans to begin development work at InterVenn Malaysia's laboratory at Technology Park Malaysia in Kuala Lumpur.

For the three months ended July 31,the firm's revenues contracted to $1.26 billion from $1.27 billion in Q3 2019, beating Wall Street analysts' average estimate of $1.21 billion.

The firm said it plans to use the proceeds to support the launch of its first product based on its structures for lossless ion manipulation ion mobility system.

The firm added $50 million from Casdin Capital, Danaher Life Sciences, and Agilent Technologies to its $38.5M Series B round announced in May 2019.